New anti-epileptic drugs

Bibliography

• SANDER JW, SHORVON SD: Epidemiology of the epilep-sies. j Neurol. Neurosurg. Psychiatry (1996) 61:433–443.
   PubMed Web of Science ®Google Scholar
• SANDER JW: Some aspects of prognosis in the epilep-sies: a review. Epilepsia (1993) 34:1007–1016.
   PubMed Web of Science ®Google Scholar
• •A review of the factors that determine prognosis in epilepsy, dispelling the idea that early treatment protects against later development of seizures.
   Google Scholar
• WALKER MC, SANDER JW: The impact of new antiepi- leptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology (1996) 46:912–914.
   PubMed Web of Science ®Google Scholar
• ••An opinion piece that argues against the current trend ofusing surrogate outcome measures in clinical trials rather than seizure freedom.
   Google Scholar
• MATTSON RH, CRAMER JA, COLLINS JF: Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology (1996) 47:68–76.
   Google Scholar
• MATTSON RH, CRAMER JA, COLLINS JF et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New Engl. J. Med. (1985) 313:145–151.
   PubMed Web of Science ®Google Scholar
• ••The major comparative monotherapy study in newlydiagnosed patients.
   Google Scholar
• WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther. (1995) 67:351–384.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JW: Overtreatment with antiepi-leptic drugs: how extensive is the problem? CNS Drugs (1994) 2:235–240.
   Web of Science ®Google Scholar
• COBB SR, BUHL EH, HALASY K, PAULSEN 0, SOMOGYI P:Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature (1995) 378:75–78.
   PubMed Web of Science ®Google Scholar
• •A paper demonstrating that paradoxically inhibitory neurones can synchronise excitatory neurones.
   Google Scholar
• WALKER MC, KULLMANN DM: Febrile convulsions - abenign condition? Nature Med. (1999) 5:871–872..
   Google Scholar
• DANOBER L, DERANSART C, DEPAULIS A, VERGNES M, MARESCAUX C: Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog. Neurobiol. (1998) 55:27–57.
   PubMed Web of Science ®Google Scholar
• ••Hypotheses and experimental studies of the mechanismsunderlying absence epilepsy.
   Google Scholar
• MACDONALD RL, MELDRUM BS: Principles of antiepi-leptic drug action. In: Anti-epileptic drugs. Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York (1995) :61–77.
   Google Scholar
• DELOREY TM, OLSEN RW: GABAA receptors: structureand function. J. Biol. Chem. (1992) 267:16747–16750.
   PubMed Web of Science ®Google Scholar
• VERGNES M, BOEHRER A, SIMLER S, BERNASCONI R, MARESCAUX C: Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur. Pharmacol (1997) 332:245–255.
   PubMed Web of Science ®Google Scholar
• •Demonstration that a drug can have opposite effects in different seizure models.
   Google Scholar
• HOSFORD DA, WANG Y: Utility of the lethargic (1h/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia (1997) 38:408–414.
   PubMed Web of Science ®Google Scholar
• ••Use of a genetic model of absence epilepsy to determine theefficacy of anti-epileptic drugs, which have been errone-ously characterised in acute seizure models.
   Google Scholar
• OZAWA S, KAMIYA H, TSUZUKI K: Glutamate receptorsin the mammalian central nervous system. Prog. Neurobiol (1998) 54:581–618.
   PubMed Web of Science ®Google Scholar
• LERMA J: Kainate receptors: an interplay between excitatory and inhibitory synapses. FEBS Lett. (1998) 430:100–104.
   PubMed Web of Science ®Google Scholar
• ••Review of recent information on kainate receptors, and theirpossible importance in epilepsy and as a target for anti-epileptic drugs.
   Google Scholar
• SVEINBJORNSDOTTIR S, SANDER JW, UPTON D et al.: Theexcitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165–174.
   PubMed Web of Science ®Google Scholar
• DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. (1998) 5:253–263.
   PubMed Web of Science ®Google Scholar
• TANG E, YIP PK, CHAPMAN AG, JANE DE, MELDRUM BS:Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats. Eur. J. Pharmacol. (1997) 327:109–115.
   PubMed Web of Science ®Google Scholar
• ABDUL GA, ATTWELL PJ, SINGH KN, BRADFORD HF, CROUCHER MJ, JANE DE: Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res. (1997) 755:202–212.
   PubMed Web of Science ®Google Scholar
• RAGSDALE DS, AVOLI M: Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Rev. (1998) 26:16–28.
   PubMed Web of Science ®Google Scholar
• ••Review of sodium channels and how more selective sodiumchannel blockers could be used to produce more effective anti-epileptic drugs.
   Google Scholar
• PUTNAM TJ, MERRITT HH: Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science (1937) 85:525
   PubMedGoogle Scholar
• GOODMAN L, TOMAN J, SWINYARD E: The anticonvul-sant properties of Tridione: laboratory and clinical investigations. Am. J. Med. (1946) 1:213.
   PubMed Web of Science ®Google Scholar
• FISHER RS: Animal models of the epilepsies. Brain Res. Brain Res. Rev. (1989) 14:245–278.
   PubMed Web of Science ®Google Scholar
• MCNAMARA JO, BONHAUS W, SHIN C: The kindling model of epilepsy. In Epilepsy. models, mechanisms, and concepts, Schwartzkroin PA (Ed.), Cambridge University Press, Cambridge, UK (1993):27–47.
   Google Scholar
• O'DONOGHUE M, SANDER JW: Does early anti-epileptic drug treatment alter the prognosis for remission of the epilepsies? J. R. Soc. Med. (1996) 89:245–248.
   Google Scholar
• LOSCHER W: Animal models of intracTable epilepsy. Prog. Neurobiol. (1997) 53:239–258.
   PubMed Web of Science ®Google Scholar
• •Description of an animal model of refractory epilepsy.
   Google Scholar
• LESCHINGER A, STABEL J, IGELMUND P, HEINEMANN U: Pharmacological and electrographic properties of epileptiform activity induced by elevated K+ and lowered Ca2+ and Mg2+ concentration in rat hippocampal slices. Exp. Brain Res. (1993) 96:230–240.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JW: Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology (1997) 49:333–337.
   PubMed Web of Science ®Google Scholar
• •Description of the divergence of regulatory trials from clinical practice (see below).
   Google Scholar
• CHADWICK D, PRIVITERA M: Placebo-controlled studies in neurology: where do they stop? Neurology (1999) 52:682–685.
   PubMed Web of Science ®Google Scholar
• •Problems with ethics and clinical applicability of some regulatory trials.
   Google Scholar
• BLUM DE, ESKOLA J, BORTZ JJ, FISHER RS: Patientawareness of seizures. Neurology (1996) 47:260–264.
   PubMed Web of Science ®Google Scholar
• VICKREY BG, HAYS RD, ENGEL J et al.: Outcome assess-ment for epilepsy surgery: the impact of measuring health-related quality of life. Ann. Neurol. (1995) 37:158–166.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the recent state of play of newanti-epileptic drugs.
   Google Scholar
• SIGEL E, BAUR R, NETZER R, RUNDFELDT C: The antiepi- leptic drug AWD 131–138 stimulates different recombi-nant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Neurosci. Lett. (1998) 245:85-88. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• CARTER RB, WOOD PL, WIELAND S et al.: Characteriza-tion of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. (1997) 280:1284–1295.
   PubMed Web of Science ®Google Scholar
• SNEAD OCI: Ganaxolone, a selective high-affinity steroid modulator of the alpha-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann. Neurol (1998) 44:688–691.
   PubMed Web of Science ®Google Scholar
• MONAGHAN EP, NAVALTA LA, SHUM L, ASHBROOK DW,LEE DA: Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia (1997) 38:1026–1031.
   PubMed Web of Science ®Google Scholar
• GOWER AJ, NOYER M, VERLOES R, GOBERT J, WULFERTE: ucb L059, a novel anti-convulsant drug: pharmacol-ogical profile in animals. Eur. J. Pharmacol. (1992) 222:193–203.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D, RUNDFELDT C: Antiepilepto-genic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. (1998) 284:474–479.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H, MATAGNE A, GOBERT J, WULFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. (1998) 353:191–206.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of how an effective anti-epileptic drug(levetiracetam) with a high therapeutic ratio would have been missed by screening in acute seizure models.
   Google Scholar
• BIRNSTIEL S, WULFERT E, BECK SG: Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch. Pharmacol. (1997) 356:611–618.
   PubMed Web of Science ®Google Scholar
• NOYER M, GILLARD M, MATAGNE A, HENICHART JP, WULFERT E: The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur.J. Pharmacol. (1995) 286:137–146.
   PubMed Web of Science ®Google Scholar
• KASTELEIJN-NOLST TD, MARESCAUX C, STODIECK S, EDELBROEK PM, OOSTING J: Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. (1996) 25:225–230.
   PubMed Web of Science ®Google Scholar
• NICOLAS JM, COLLART P, GERIN B et al.: In vitro evalua-tion of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. (1999) 27:250–254.
   PubMed Web of Science ®Google Scholar
• KOHR G, HEINEMANN U: Effects of the tetronic acidderivatives A033 (losigamone) and A078 on epilepti-form activity and on stimulus-induced calcium concentration changes in rat hippocampal slices. Epilepsy Res. (1990) 7:49–58.
   PubMed Web of Science ®Google Scholar
• ZHANG CL, CHATTERJEE SS, STEIN U, HEINEMANN U Comparison of the effects of losigamone and its isomers on maximal electroshock induced convul-sions in mice and on three different patterns of low magnesium induced epileptiform activity in slices of the rat temporal cortex. Naunyn Schmiedebergs Arch. Pharmacol. (1992) 345:85–92.
   PubMed Web of Science ®Google Scholar
• LESCHINGER A, STABEL J, IGELMUND P, HEINEMANN U:Pharmacological and electrographic properties of epileptiform activity induced by elevated K+ and lowered Ca2+ and Mg2+ concentration in rat hippocampal slices. Exp. Brain Res. (1993) 96:230–240.
   PubMed Web of Science ®Google Scholar
• SCHMITZ D, GLOVELI T, HEINEMANN U: Effects of losigamone on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocampal CA1 neurones. Neurosci. Lett. (1995) 200:141–143.
   PubMed Web of Science ®Google Scholar
• YONEKAWA WD, KAPETANOVIC IM, KUPFERBERG HJ: The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res. (1995) 20:137–150.
   PubMed Web of Science ®Google Scholar
• KAPETANOVIC IM, YONEKAWA WD, KUPFERBERG HJ: The effects of anticonvulsant compounds on 4-aminopyridine-induced de novo synthesis of neurotransmitter amino acids in rat hippocampus in vitro. Epilepsy Res. (1995) 20:113–120.
   PubMed Web of Science ®Google Scholar
• ZIEMANN U, LONNECKER S, STEINHOFF BJ, PAULUS W: Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann. Neurol. (1996) 40:367–378.
   PubMed Web of Science ®Google Scholar
• DRAGUHN A, JUNGCLAUS M, SOKOLOWA S, HEINEMANN U: Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons. Eur. J. Pharmacol. (1997) 325:245–251.
   PubMed Web of Science ®Google Scholar
• DIMPFEL W, CHATTERJEE SS, NOLDNER M, TICKU MK: Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system. Epilepsia (1995) 36:983–989.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN J, RICHENS A, DAVIES JA: The effect of losigamone (A0-33) on electrical activity and excita-tory amino acid release in mouse cortical slices. Br. J. Pharmacol. (1997) 122:1490–1494.
   PubMed Web of Science ®Google Scholar
• BIBER A, DIENEL A: Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:6–11.
   PubMed Web of Science ®Google Scholar
• PEETERS PA, VAN-LIER JJ, VAN-DE-MERBEL N et al.: Pharmacokinetics of [14C]-labelled Losigamone and enantiomers after oral administration to healthy subjects. Eur. J. Drug Metab. Pharmacokinel (1998) 23:45–53.
   PubMed Web of Science ®Google Scholar
• TAYLOR CP, VARTANIAN MG, ANDRUSZKIEWICZ R, SILVERMAN RB: 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. (1992) 11:103–110.
   PubMed Web of Science ®Google Scholar
• TAYLOR CP, VARTANIAN MG, YUEN PW, BIGGE C, SUMAN CN, HILL DR: Potent and stereospecific anticon-vulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. (1993) 14:11–15.
   PubMed Web of Science ®Google Scholar
• BRYANS JS, WUSTROW DJ: 3-substituted GABA analogswith central nervous system activity: a review. Med. Res. Rev. (1999) 19:149-177. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• STAGNITTO ML, PALMER GC, ORDY JM et al.: Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res. (1990) 7:11–28.
   PubMed Web of Science ®Google Scholar
• GARSKE GE, PALMER GC, NAPIER JJ et al.: Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res. (1991) 9:161–174.
   PubMed Web of Science ®Google Scholar
• PALMER GC, MURRAY RJ, WILSON TC et al.: Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res. (1992) 12:9–20.
   PubMed Web of Science ®Google Scholar
• WAMIL AW, CHEUNG H, HARRIS EW, MCLEAN MJ: Remacemide HC1 and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Epilepsy Res. (1996) 23:1–14.
   PubMed Web of Science ®Google Scholar
• NORRIS SK, KING AE: Electrophysiological effects of theanticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology (1997) 36:951–959.
   PubMed Web of Science ®Google Scholar
• PALMER GC, CREGAN EF, BORRELLI AR, WILLETT F: Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochlo-ride. Ann. NY Acad. ScL (1995) 765:236–247.
   PubMed Web of Science ®Google Scholar
• MUIR KT, PALMER GC: Remacemide. Epilepsy Res. Suppl.(1991) 3:147–152.
   PubMedGoogle Scholar
• HEYN H, MCCARTHY DJ, CURRY SH, EISMAN MS, ANDERS MW: Brain uptake and biotransformation of remace-mide hydrochloride, a novel anticonvulsant. Drug Metab. Dispos. (1994) 22:443–446.
   PubMed Web of Science ®Google Scholar
• LEACH JP, BLACKLAW J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Mutual interaction between remace-mide hydrochloride and carbamazepine: two drugs with active metabolites. Epilepsia (1996) 37:1100–1106.
   PubMed Web of Science ®Google Scholar
• LEACH JP, GIRVAN J, JAMIESON V, JONES T, RICHENS A, BRODIE MJ: Mutual interaction between remacemide hydrochloride and phenytoin. Epilepsy Res. (1997) 26:381–388.
   PubMed Web of Science ®Google Scholar
• ROSTOCK A, TOBER C, RUNDFELDT C et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211–223.
   PubMed Web of Science ®Google Scholar
• DAILEY JW, CHEONG JH, KO KH, ADAMS CL, JOBE PC: Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci.Lett. (1995) 195:77–80.
   PubMed Web of Science ®Google Scholar
• TOBER C, ROSTOCK A, RUNDFELDT C, BARTSCH R: D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. (1996) 303:163–169.
   PubMed Web of Science ®Google Scholar
• KAPETANOVIC IM, YONEKAWA WD, KUPFERBERG HJ: The effects of D-23129, a new experimental anticon-vulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res. (1995) 22:167–173.
   PubMed Web of Science ®Google Scholar
• RUNDFELDT C: The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. (1997) 336:243–249.
   PubMed Web of Science ®Google Scholar
• MCNEILLY PJ, TORCHIN CD, ANDERSON LW, KAPETANOVIC IM, KUPFERBERG HJ, STRONG JM: In vitro glucuronidation of D-23129, a new anticonvul-sant, by human liver microsomes and liver slices. Xenobiotica (1997) 27:431–441.
   PubMed Web of Science ®Google Scholar
• CARDOT JM, LECAILLON JB, CZENDLIK C, GODBILLON J: The influence of food on the disposition of the antiepi-leptic rufmamide in healthy volunteers. Biopharm. Drug Dispos. (1998) 19:259–262.
   PubMed Web of Science ®Google Scholar
• MARTIN SW, BISHOP FE, KERR BM et al.: Pharmacoki-netics and metabolism of the novel anticonvulsant agent N- (2,6-dimethylpheny1)-5-methy1-3-4soxazolecarboxamide (D2624) in rats and humansl. Drug Metab. Dispos. (1997) 25:40–46.
   PubMed Web of Science ®Google Scholar
• MAURIZIS JC, MADELMONT JC, RAPP M et al.: Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazoly0 (D2916) in male and female rats. Drug Metab. Dispos. (1997) 25:33–39.
   PubMed Web of Science ®Google Scholar